Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Fig. 5

5A, PFS according to immune-related toxicity; 5B, OS according to immune-related toxicity; 5C, PFS in patients treated with pembrolizumab-based chemoimmunotherapy according to immune-related toxicity; 5D, OS in patients treated with pembrolizumab-based chemoimmunotherapy according to immune-related toxicity; 5E, PFS in patients treated with pembrolizumab monotherapy according to immune-related toxicity; 5F, OS in patients treated with pembrolizumab monotherapy according to immune-related toxicity

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us